ZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Bioorg Med Chem. 2013 Sep 15;21(18):5679-87. doi: 10.1016/j.bmc.2013.07.034. Epub 2013 Jul 25.
A series of novel benzyl-substituted (S)-phenylalanine derivatives were synthesized and evaluated for their dipeptidyl peptidase 4 (DPP-4) inhibitory activity and selectivity. It was found that most synthesized target compounds were potent DPP-4 inhibitors with IC50 values in 3.79-25.52 nM, which were significantly superior to that of the marketed drug sitagliptin. Furthermore, the 4-fluorobenzyl substituted phenylalanine derivative 6g not only displayed the potent DPP-4 inhibition with an IC50 value of 3.79 nM, but also showed better selectivity against DPP-4 over other related enzymes including DPP-7, DPP-8, and DPP-9. In an oral glucose tolerance test (OGTT) in normal Sprague Dawley rats, compound 6g reduced blood glucose excursion in a dose-dependent manner.
一系列新型苄基取代的(S)-苯丙氨酸衍生物被合成并评估了它们的二肽基肽酶 4(DPP-4)抑制活性和选择性。结果发现,大多数合成的目标化合物都是强效的 DPP-4 抑制剂,IC50 值在 3.79-25.52 nM 之间,明显优于市售药物西他列汀。此外,4-氟苄基取代的苯丙氨酸衍生物 6g 不仅表现出强效的 DPP-4 抑制作用,IC50 值为 3.79 nM,而且对 DPP-4 相对于其他相关酶(包括 DPP-7、DPP-8 和 DPP-9)具有更好的选择性。在正常 Sprague Dawley 大鼠的口服葡萄糖耐量试验(OGTT)中,化合物 6g 以剂量依赖性方式降低血糖波动。